Background-Paraneoplastic neurological syndromes (PNS) are inflammatory disorders that probably depend on autoimmune processes. Several autoantibodies (anti-Hu, anti-Ri, and anti-Yo) have been characterised in PNS and proved to be helpful in the diagnosis. However, these do not account for all the cases and the possibility that other types of antibodies could be detected was investigated. Methods and results-Of 45 patients with PNS whose serum was probed on paraformaldehyde fixed rat brain sections, 11 patients were identified whose serum samples recognised a cytoplasmic antigen in a subpopulation of glial cells in the white matter of adult rat brainstem, cerebellum, and spinal cord that were double labelled with a monoclonal antibody specific for oligodendrocytes. All serum samples reacted with a 66 kDa protein of newborn rat brain on western blot analysis. These antibodies were designated as anti-CV2 antibodies. Only one of the 11 patients had one of the well characterised autoantibodies (anti-Hu). Five patients had cerebellar degeneration, three had limbic encephalitis, two had encephalomyelitis, and one had LambertEaton myasthenic syndrome. The tumours were small cell lung cancer or undifferentiated mediastinal cancer in seven patients, uterine sarcoma in two, and malignant thymoma in two. Among 1061 control serum samples, only two patients had anti-CV2 antibodies. One had small cell lung cancer and the other malignant thymoma. Conclusions-The detection of anti-CV2 antibodies in patients with neurological
Paraneoplastic neurological syndromes (PNS) are rare inflammatory disorders of the central and peripheral nervous system' that possibly depend on autoimmune processes directed against antigens shared between the tumour and the nervous system.2 Several autoantibodies correlated with the neurological disorders and the tumours have been characterised in PNS and proved to be helpful in the diagnoSiS. 3 Thus most patients with the encephalomyelitis-sensory neuropathy complex associated with anti-Hu (or ANNA-1) antibodies have small cell lung cancer.5 6 Those with paraneoplastic cerebellar degeneration and anti-Yo (or PCA-1) antibodies have gynaecological tumours.7 8 Most of the patients with anti-Ri (or ANNA-2) antibodies and opsoclonus/ataxia have breast cancers.9 However, these autoantibodies do not account for all patients with PNS.10-12 Some of the patients negative for these antibodies could actually harbour autoantibodies that could be identified by other methods, in particular, by using fixing procedures which improve antigen preservation.
Recently, by using paraformaldehyde fixed rat brain sections, we described two patients with PNS and antibodies that reacted with a cytoplasmic antigen in a subpopulation of glial cells in the brainstem and cerebellar white matter.'314 To investigate the possibility that these antibodies could be relevent for the diagnosis of cancer in patients with neurological disorders suspected to be paraneoplastic, we screened 45 patients with PNS, 128 patients with tumour, and 933 control patients of various types for the presence of these antibodies.
Materials and methods

PATIENTS
Serum and CSF from 45 patients with PNS were collected and stored at -20°C until use. Control serum samples were obtained from 900 patients with various inflammatory or non-inflammatory neurological diseases without cancer, 128 patients with cancer and no PNS (37 small cell lung carcinoma, 14 other lung cancer, 25 intestinal adenocarcinoma, two lymphoma, 29 gynaecological cancer (breast and ovary), seven various carcinomas, 14 malignant thymoma with myasthenia gravis) and 33 normal control subjects. Control CSF samples were obtained from 30 patients with various neurological syndromes.
As positive controls for the identification of anti-Hu, anti-Ri, and anti-Yo antibodies, we used three serum samples obtained from Dr Josep Dalmau (Memorial Sloan Kettering Cancer Center, New York, USA).
TISSUE PREPARATION FOR IMMUNOHISTOCHEMISTRY
Adult rat, newbom rat, and day 22 rat embryonic tissues (E22) were obtained from OFA 270 group.bmj.com on May 6, 2017 -Published by http://jnnp.bmj.com/ Downloaded from rats (IFFA CREDO, France). Human brain samples were obtained from a 71 year old woman without neurological disease and from a 24 week embryo after a spontaneous abortion.
Adult rats were anaesthetised with Nembutal and killed by intracardiac perfusion of 4% paraformaldehyde and 0-2% picric acid diluted in phosphate buffer (0 1 M, pH 7.4). Tissues were postfixed for 24 hours at 4°C in the same solution, rinsed in phosphate buffer for 12 hours, cryoprotected in a solution of 25% sucrose in phosphate buffer, rapidly frozen in isopentane chilled at -60°C in liquid nitrogen, and stored at -80°C. Human brain, rat embryo, and newborn rat brain were fixed at 4°C for four days by immersion in 4% paraformaldehyde and 0-2% picric acid diluted in phosphate buffer (01 M, pH 7 4) and then cryoprotected as described above.
IMMUNOCYTOCHEMISTRY Immunofluorescence
To screen the serum samples we used an indirect immunofluorescence technique. Frozen sections (12 pm) were cut on a cryostat, mounted on gelatin-covered slides, treated for two hours in phosphate buffered saline (PBS) and 1% bovine serum albumin (BSA) with 0-1% Triton X 100, and incubated for 12 hours with the patient's serum in PBS-1% BSA at room temperature (diluted 1/100 on adult rat brain sections and 1/1000 on E22 rat embryo sections). After three washes with PBS-1% BSA-0-1% Triton X 100, the sections were incubated for two hours with 1/100 diluted fluorescein-conjugated rabbit antihuman antiserum (Dakopatts, Denmark) in PBS-1% BSA. After washing in PBS, the slides were mounted in moviol and examined with an Axiophot Zeiss microscope. Control sections were incubated with either fluorescein conjugated antihuman IgG antiserum alone, patient's serum alone, or control serum samples and the fluorescein conjugated antibody at the same dilution. Positive serum samples were then tested to establish end point dilution.
Immunoperoxidase
To confirm the positivity of the serum samples detected by screening with immunofluorescence, we used both indirect and direct immunoperoxidase labelling after biotinylation of the patient's serum IgG. Indirect immunoperoxidase method-Frozen tissue sections fixed by paraformaldehyde were sequentially incubated with 0-3% hydrogen peroxide (to destroy tissue peroxydase activity) and 10% normal rabbit serum (to prevent non-specific binding of rabbit IgG) or 1% BSA. After incubation for 12 hours with patient's serum diluted 1/1000 and washes, the sections were incubated for two hours with biotinylated rabbit antihuman IgG antiserum (Jackson, Baltimore, USA) diluted 1/1000 in PBS-1% BSA. Bound human IgG was vizualised by incubation with avidin-biotinperoxidase (Vectastain ABC complex, Vector) and developed with 0-05% diaminobenzidine tetrahydrochloride (Sigma, St Louis, MO). 
Subcellularfractionation of brain
Samples of fresh rat or postmortem human brain were homogenised with sodium phosphate buffer (5 mM, pH 7) containing protease inhibitors (1/1000 leupeptine, 1/1000 pepstatine, 2-5/1000 aprotinine (Sigma)), and 0-3 M sucrose, using a hand held teflon glass potter homogeniser (clearance 0-1 mm) and centrifuged for 10 minutes at 1000 g to remove nuclei and large tissue fragments. In some experiments, the supernatant (S1) was then centrifuged for one hour at 6000 g. The pellet (P2) contained a crude membrane fraction. The supernatant (S2) was then centrifuged for 30 minutes at 100 000 g to separate soluble proteins (S3) from a crude microsome fraction (P3). The fractions P2, S3, and P3 were then diluted with buffer containing protease inhibitors to adjust the protein concentration to 1 mg/ml and stored at -200C.
Immunoblotting
Each fraction was diluted and the associated tumours. In eight pa (1, 2, 3, 5, 7, 8, 9 , and 11), the neurol syndromes preceded the discovery o tumour by one to 24 months. In the patients (4, 6, and 10) in whom neurol symptoms occurred after the diagnosis 4 tumour, the tumour was not in remissi that time. Seven patients had small cell cancer, two had uterine sarcoma, and tw lymphoepithelial malignant thymoma. In three patients (2, 3, and 7), the symptoms consisted of epilepsy and X memory impairment which were highly gestive of limbic encephalitis. In two of (patients 2 CV2 antiserum was clearly different from that with anti-Hu antibodies which labelled the nuclei of neurons and at low dilution the itients nuclei of glial cells (data not shown). By logical immunofluorescence, the limiting dilution of if the anti-CV2 serum antibodies from the 11 three patients with PNS and the two positive logical patients with cancer and no PNS ranged from of the 1/1000 to 1/100 000. The anti-CV2 antibody ion at titre from the seven CSF samples available I lung ranged from 1/100 to 1/2000. In the patient ro had who also had anti-Hu antibodies (patient 5), serum anti-Hu antibody titre was 1/60 000 by main our immunohistochemistry technique on rat recent brain whereas it was 1/100 000 for anti-CV2 { sug-antibodies. In addition, four out of the 11 them serum samples of patients with anti-CV2 anti-I hip-bodies and PNS labelled cells in the subgranuighted lar layer of the dentate gyrus of the had a hippocampus at 1/1000 to 1/10000 dilution ivo of (patient 1, 2, 7, and 11). At low dilution tients (1/100) some serum samples with anti-CV2 idden antibodies labelled the cytoplasm of neurons lepsy, in the thalamus, the cortex, or the hippocamient 5 pus whereas no labelling was seen on adult rat bellar liver, kidney, testes, ovary, spleen, and adrenal ibert-gland. Immunoperoxidase on a six week old rat cerebellum with biotinylated IgG of patient 7 (1 ,ug/ml) (original magnification x 400). m = Molecular layer; g = granular layer; wm = white matter. ( remained positive at 1/1000 dilution (patients 2, 5, and the patient with small cell lung cancer and no PNS). Western blots of the S3 soluble fraction of adult rat brain showed lower levels of expression of the 66 kDa protein than in newborn rat brain and three serum samples gave no staining (patients 6, 8, and 10).
In the S3 fraction of human embryo brain, nine of the 11 serum samples of patients with PNS and the serum samples of the two positive patients with cancer and no PNS labelled a 66 kD band at 1/100 and 1/500 dilutions. Patients 6 and 10 were negative. With the S3 fraction of adult human brain, six serum samples (patients 2, 4, 5, 7, 9, and 11) reacted with a 66 kDa band with variable staining intensities whereas the other serum samples were negative.
IMMUNOPRECIPITATION
To test whether these serum samples recognised the same antigen, we immunoprecipitated the S3 soluble fraction of newborn rat brain with the serum samples from patients 2 and 5. On the immunoprecipitated extracts, the seven anti-CV2 antiserum samples tested (from patients 1 to 7) recognised the 66 kDa band (weakly for serum 6; fig 9) and the band was not recognised in either of the two serum samples of normal control patients. No band was recognised by anti-CV2 serum samples in the extracts immunoprecipitated with the control serum.
Discussion
The identification of the well characterised autoantibodies-anti-Hu (ANNA-1), anti-Ri (ANNA-2), and anti-Yo (PCA-1)-associated with PNS relies on immunohistochemical and western blot methods.3 4 Immunohistochemistry is usually performed on acetone fixed sections from human or rodent brain and only high serum dilutions are considered. Obviously, further work is needed to purify the 66 kDa protein for routine western blots with higher serum dilution. The availability of a recombinant protein, currently in progress, will probably improve the sensibility of western blots. Anti-CV2 antibodies are strongly associated with cancer, predominantly in patients with PNS. However, they do not seem to be specific for one type of neurological disorder nor of one type of tumour. Indeed, although anti-CV2 antibodies seem to be mainly associated with small cell lung cancer, they occur in several cases with uterine sarcoma or malignant thymoma and a range of neurological syndromes including Lambert-Eaton myasthenic syndrome, limbic encephalitis, encephalomyelitis, and cerebellar degeneration. However, all of these neurological syndromes are known to be paraneoplastic. ' One of the criteria proposed for the characterisation of antibodies associated with PNS is that these antibodies should react with neurons in regions corresponding to the neurological syndrome. 17 This presupposes that the antibodies are the primary mediator of the immune attack. For the moment, this hypothesis needs confirmation.2 Indeed, although some data suggest that anti-Hu antibodies could provoke lysis and subsequently neuronal death,'4 other studies failed to confirm this hypothesis.2'5 Alternatively, the antibodies may be only part of a complex autoimmune reaction involving several tumour and brain antigens and several effectors of humoral and cellular immunity.'6 Thus a polyclonal activation of B cells could lead to the production of antibodies that are not directly involved in the autoimmune process.4 Antistriated muscle antibodies are a good example of this phenomenon in patients with myasthenia gravis and thymoma.27 Whether anti-CV2 antibodies result from a polyclonal activation or are directly involved in the PNS remains to be established. Anti-CV2 antibodies react, in adult brain, with a subpopulation of oligodendrocytes, a cell class that is not considered to However, whatever the physiopathological relevance of anti-CV2 antibodies, their detection is valuable in the diagnosis of PNS. Indeed, 10 out of the 11 patients with PNS and anti-CV2 antibodies were negative for anti-Hu, anti-Ri, or anti-Yo antibodies. In four cases investigated before the discovery of the tumour, the detection of anti-CV2 antibodies predicted the presence of a cancer with the high probability that it was a small cell lung cancer. This was confirmed in each case by the discovery of mediastinal lymph nodes on chest CT. If a chest CT is negative for thymoma or metastatic lymph nodes, patients with anti-CV2 antibodies should be preferentially investigated for uterine sarcoma. 
